The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area. The main aims of the SIG are:
- To understand how best to apply Benefit-Risk Methodologies across the Pharmaceutical Industry
- To discuss and make recommendations on key methodological issues
- To share examples of how Benefit-Risk has been used within pharmaceutical companies
- To share external information including new developments around Benefit-Risk – See more here
This working group is part of the PSI and EFSPI. Please contact Alexander Schacht (email@example.com) if you would like to become a member.